Pharma M&A boost from expanded drug and service access, plus outsourcing trends
'We’ve seen several high-profile transactions in life sciences, resulting in big exits for investors in the private and public markets,' said Toby Sykes, managing director of Intermediate Capital Group.
2 January 2025•3 mins read
